Enhancing Treatment Adherence Personalized support programs, digital tracking apps, and behavioral counseling could improve adherence
Topical GHK-Cu at 1 to 3% concentration is effective for localized skin and hair benefits
Gambarotta G, Boccaccio C, Giordano S, And M, Stella MC, Comoglio PM (November 1996)
If injection site reactions are severe, persistent, or associated with signs of infection (warmth, purulent drainage, systemic symptoms), further evaluation and possible treatment modification may be warranted
Organs (2022)
Your complete medical history , including: Any history of kidney disease or current kidney function status Previous episodes of diabetic ketoacidosis or pancreatitis Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (these are not formal contraindications in the UK for Wegovy, but require discussion) Cardiovascular disease, including heart failure Any history of recurrent urinary or genital infections Previous problems with dehydration or low blood pressure All current medications and supplements , as interactions may occur with: Insulin or other injectable diabetes medications Sulphonylureas (e.g., gliclazide, glimepiride) Other medications that affect kidney function Diuretics or blood pressure medications Warfarin or other anticoagulants (INR should be monitored when starting semaglutide) Your treatment goals and expectations : Discuss what you hope to achieve with this combination therapy, whether primarily glucose control, weight loss, cardiovascular risk reduction, or a combination of these outcomes
